GoAI
Get started
Glaukos Corporation logo

Glaukos Corporation

GKOS

NYSEHealthcareMedical - Devices

Open in GoAI

Previous close

$184.89

$0.00 · 0.00%

Aug 21, 4:00 PM ET

Pre-market

$185

+$0.11 · +0.06%

Aug 24, 6:09 AM ET

GKOS company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

72

Gaining

Sentiment

60

Mixed

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Thomas William Burns
Listed since
Jun 25, 2015
Employees
1,094

Market position

Day range

Current $184.89

52-week range

Current $184.89

Open
$184.99
Previous close
$184.89
Volume
348.61K
0.37× average
Average volume
942.3K
Average daily volume
Market cap
10.91B USD
Beta
0.76
Market reference 1
50-day average
$156.87
+17.86% above average
200-day average
$124.71
+48.26% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.51B USD
P/E (TTM)
-56.89×
P/B (TTM)
15.83×
P/S (TTM)
17.8×
EV / EBITDA
-44.54×
Earnings yield
-2.91%
Free cash flow yield
-0.84%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
79.12%
Operating margin
-13.13%
Net margin
-30.68%
Return on equity
-28.60%
Return on assets
-21.01%
Return on invested capital
-10.64%

Financial health

Debt / equity
0.15×
Current ratio
4.69×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%41%-7%-55%Gross margin, FY2021: 77.34%Gross margin, FY2022: 75.61%Gross margin, FY2023: 75.99%Gross margin, FY2024: 75.48%Gross margin, FY2025: 77.49%Operating margin, FY2021: -11.18%Operating margin, FY2022: -29.10%Operating margin, FY2023: -40.89%Operating margin, FY2024: -31.91%Operating margin, FY2025: -17.09%Net margin, FY2021: -16.87%Net margin, FY2022: -35.07%Net margin, FY2023: -42.79%Net margin, FY2024: -38.17%Net margin, FY2025: -36.99%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 77.34%. Gross margin FY2022 75.61%. Gross margin FY2023 75.99%. Gross margin FY2024 75.48%. Gross margin FY2025 77.49%. Operating margin FY2021 -11.18%. Operating margin FY2022 -29.10%. Operating margin FY2023 -40.89%. Operating margin FY2024 -31.91%. Operating margin FY2025 -17.09%. Net margin FY2021 -16.87%. Net margin FY2022 -35.07%. Net margin FY2023 -42.79%. Net margin FY2024 -38.17%. Net margin FY2025 -36.99%.

Income trends

Revenue

507.44M USD+32.33%

Operating income

−86.73M USD+29.12%

Net income

−187.69M USD-28.23%
Income trends across reported periods576.96M USD298.9M USD20.85M USD−257.2M USDRevenue, FY2021: 294.01M USDRevenue, FY2022: 282.86M USDRevenue, FY2023: 314.71M USDRevenue, FY2024: 383.48M USDRevenue, FY2025: 507.44M USDOperating income, FY2021: −32.87M USDOperating income, FY2022: −82.31M USDOperating income, FY2023: −128.7M USDOperating income, FY2024: −122.37M USDOperating income, FY2025: −86.73M USDNet income, FY2021: −49.59M USDNet income, FY2022: −99.2M USDNet income, FY2023: −134.66M USDNet income, FY2024: −146.37M USDNet income, FY2025: −187.69M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 294.01M USD. Revenue FY2022 282.86M USD. Revenue FY2023 314.71M USD. Revenue FY2024 383.48M USD. Revenue FY2025 507.44M USD. Operating income FY2021 −32.87M USD. Operating income FY2022 −82.31M USD. Operating income FY2023 −128.7M USD. Operating income FY2024 −122.37M USD. Operating income FY2025 −86.73M USD. Net income FY2021 −49.59M USD. Net income FY2022 −99.2M USD. Net income FY2023 −134.66M USD. Net income FY2024 −146.37M USD. Net income FY2025 −187.69M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue507.44M USD383.48M USD314.71M USD282.86M USD294.01M USD
Cost of goods sold114.23M USD94.03M USD75.58M USD68.98M USD66.63M USD
Gross profit393.22M USD289.45M USD239.14M USD213.88M USD227.38M USD
Research and development150.61M USD136.43M USD138.77M USD123.27M USD101M USD
Selling, general, and administrative329.34M USD262.85M USD224.07M USD192.93M USD179.26M USD
Operating expenses479.95M USD411.82M USD367.84M USD296.2M USD260.26M USD
Interest income10.71M USD11.11M USD9.16M USD2.38M USD1.29M USD
Interest expense4.64M USD10.04M USD13.63M USD13.72M USD13.37M USD
Depreciation and amortization42.35M USD39.92M USD37.98M USD35.95M USD34.42M USD
Operating income−86.73M USD−122.37M USD−128.7M USD−82.31M USD−32.87M USD
Net income−187.69M USD−146.37M USD−134.66M USD−99.2M USD−49.59M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+12.34%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.21 · Beat by 33.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.21-0.33-0.44Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual -0.4, estimate -0.38, surprise -5.26%, Miss. Q2 2025, reported Apr 30, 2025: actual -0.22, estimate -0.33, surprise +33.33%, Beat. Q3 2025, reported Jul 30, 2025: actual -0.24, estimate -0.26, surprise +7.69%, Beat. Q4 2025, reported Oct 29, 2025: actual -0.16, estimate -0.27, surprise +40.74%, Beat. Q1 2026, reported Feb 17, 2026: actual -0.28, estimate -0.22, surprise -27.27%, Miss. Q2 2026, reported Apr 29, 2026: actual -0.18, estimate -0.3, surprise +40.00%, Beat. Q3 2026, reported Jul 29, 2026: actual -0.14, estimate -0.211, surprise +33.50%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates193.03M159.87M126.7M93.53MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 105.5M USD, estimate 100.96M USD, surprise +4.50%, Beat. Q2 2025, reported Apr 30, 2025: actual 106.66M USD, estimate 102.78M USD, surprise +3.78%, Beat. Q3 2025, reported Jul 30, 2025: actual 124.12M USD, estimate 122.43M USD, surprise +1.38%, Beat. Q4 2025, reported Oct 29, 2025: actual 133.54M USD, estimate 129.46M USD, surprise +3.15%, Beat. Q1 2026, reported Feb 17, 2026: actual 143.12M USD, estimate 136.4M USD, surprise +4.93%, Beat. Q2 2026, reported Apr 29, 2026: actual 150.57M USD, estimate 137M USD, surprise +9.91%, Beat. Q3 2026, reported Jul 29, 2026: actual 185.61M USD, estimate 150.93M USD, surprise +22.97%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 167.93M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$190.75

3.17% upside
Past 12 months12-month forecast

Price history unavailable

High $215Average $190.75Low $150

Rating distribution

25 ratings
Strong buy00%
Buy1872%
Hold624%
Sell14%
Strong sell00%

Recent analyst actions

12 institutions
HC Wainwright & Co.maintainBuy

GKOS peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding GKOS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
663.62M
Weight
0.59%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
296.68M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
271.55M
Weight
0.34%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
213.91M
Weight
0.12%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
123.8M
Weight
0.28%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
112.74M
Weight
0.12%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
102.17M
Weight
0.60%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
99.08M
Weight
0.66%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research GKOS

research.disclaimer